OSI-930

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C22H16F3N3O2S
Molecular Weight	443.442
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

FC(F)(F)OC1=CC=C(NC(=O)C2=C(NCC3=CC=NC4=CC=CC=C34)C=CS2)C=C1

InChI

InChIKey=FGTCROZDHDSNIO-UHFFFAOYSA-N

InChI=1S/C22H16F3N3O2S/c23-22(24,25)30-16-7-5-15(6-8-16)28-21(29)20-19(10-12-31-20)27-13-14-9-11-26-18-4-2-1-3-17(14)18/h1-12,27H,13H2,(H,28,29)

HIDE SMILES / InChI

Molecular Formula	C22H16F3N3O2S
Molecular Weight	443.442
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23403628 | https://www.astellas.com/en/corporate/news/pdf/100517_eg_2.pdf

OSI-930 (now SIM-930) is a potent, oral small-molecule receptor tyrosine kinase inhibitor, which acts predominantly against VEGF receptors (VEGFR), c-Kit, and platelet-derived growth factor receptors. OSI-930 has a pharmacokinetic-pharmacodynamic profile distinct from other RTK inhibitors, with potent antitumor activity in multiple xenograft models. OSI-930 passed through phase I clinical trial in the USA (in patients with advanced solid tumors) and recieved the clinical approval by China FDA after being out-licensed to Simcere Pharma in China.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Mast/stem cell growth factor receptor Kit 5 Target ID: P10721 Gene ID: 3815.0 Gene Symbol: KIT Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/16424037	Inhibitor 8297	80.0 nM [IC50]
Platelet-derived growth factor subunit B 1 Target ID: P01127 Gene ID: 5155.0 Gene Symbol: PDGFB Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/16424037	Inhibitor 8297	6900.0 nM [IC50]
Vascular endothelial growth factor receptor 2 104 Target ID: P35968 Gene ID: 3791.0 Gene Symbol: KDR Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/16424037	Inhibitor 8297	9.0 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Advanced solid cancer 28 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23099006	Primary		Phase I 428	Unknown Approved Use Unknown

C_max

Value	Dose	Analyte	Population
2.03 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23403628	600 mg 2 times / day multiple, oral dose: 600 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OSI-930 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
1.07 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23403628	1600 mg 1 times / day multiple, oral dose: 1600 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OSI-930 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
1.01 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23403628	500 mg 2 times / day multiple, oral dose: 500 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OSI-930 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED

AUC

Value	Dose	Analyte	Population
11.9 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23403628	600 mg 2 times / day multiple, oral dose: 600 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OSI-930 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
13 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23403628	1600 mg 1 times / day multiple, oral dose: 1600 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OSI-930 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
5.76 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23403628	500 mg 2 times / day multiple, oral dose: 500 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OSI-930 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED

T_1/2

Value	Dose	Analyte	Population
5.39 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23403628	600 mg 2 times / day multiple, oral dose: 600 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OSI-930 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
12.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23403628	1600 mg 1 times / day multiple, oral dose: 1600 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OSI-930 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED
7.11 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/23403628	500 mg 2 times / day multiple, oral dose: 500 mg route of administration: Oral experiment type: MULTIPLE co-administered:	OSI-930 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FED

Sourcing

Vendor/Aggregator	ID	URL
001 Chemical	DY111460	https://www.001chemical.com/chem/search?q=DY111460
1PlusChem LLC	1P00FCHD	https://www.1pchem.com/search?query=1P00FCHD
AK Scientific	X7484	https://aksci.com/item_detail.php?cat=X7484
AOBIOUS INC	AOB87749	http://aobious.com/aobious/search?search_query=AOB87749
ApexBio Technology	A2838	https://www.apexbt.com/catalogsearch/result/?q=A2838
AstaTech	F20785	http://astatechinc.com/CPSResult.php?CRNO=F20785
Axon MedChem	1547	https://www.axonmedchem.com/product/1547
BLD Pharm	BD341718	http://www.bldpharm.com/search/Search.html?keyword=BD341718
BOC Sciences	728033-96-3	http://www.bocsci.com/description.asp?cas=728033-96-3
Chem Scene	CS-0174	http://www.chemscene.com/goproductList/searchProductList?productObj=CS-0174
ChemShuttle	104814	https://www.chemshuttle.com/catalogsearch/result/?q=104814
Excenen	EX-A2118	http://www.excenen.com/searchresultlist.php?id=EX-A2118
KeyOrganics	AS-55949	http://www.keyorganicsinc.com/bionet/catalogsearch/result?q=AS-55949
Lab Seeker	SC-94558	http://www.labseeker.com/search.php?keywords=SC-94558&category=0
LabSeeker	SC-94558	http://www.labseeker.com/search.php?keywords=SC-94558&category=0
Matrix Scientific	145209	http://www.matrixscientific.com/145209.html
MedChem Express	HY-10204	https://www.medchemexpress.com/search.html?q=HY-10204&ft=&fa=&fp=
MolPort	MolPort-009-679-500	https://www.molport.com/shop/molecule-link/MolPort-009-679-500
Molcore	MC111460	http://www.molcore.com/CatMC111460.html
Molnova	M15785	https://www.molnova.com/en/serch-list.html?keywords=M15785
MuseChem	I004709	https://www.musechem.com/product/I004709.html
ShangHai Biochempartner	BCP000252	http://www.biochempartner.com/search_BCP000252
ShangHai Biochempartner	BCP02118	http://www.biochempartner.com/search_BCP02118
TargetMol	T2624	https://www.targetmol.com/search?keyword=T2624
eMolecules	32176522	https://orderbb.emolecules.com/search/#?query=32176522
eNovation Chemicals	D371746	https://www.enovationchem.com/Products.asp?SEARCHTEXT=D371746&searchbtn.x=0&searchbtn.y=0
mcule	MCULE-5690326995	https://mcule.com/MCULE-5690326995/

PubMed

Title	Date	PubMed
		252160242
Cytochrome P450 oxidation of the thiophene-containing anticancer drug 3-[(quinolin-4-ylmethyl)-amino]-thiophene-2-carboxylic acid (4-trifluoromethoxy-phenyl)-amide to an electrophilic intermediate.	2008 Aug	18672911
First-in-human phase I trial of two schedules of OSI-930, a novel multikinase inhibitor, incorporating translational proof-of-mechanism studies.	2013 Feb 15	23403628
A phase 1 study of OSI-930 in combination with erlotinib in patients with advanced solid tumours.	2013 Mar	23099006

Patents

Sample Use Guides

In Vivo Use Guide

The maximum-tolerated dose is 500 mg given twice a day.

Route of Administration: Oral

In Vitro Use Guide

HMC-1 mast cell leukemia cells, COLO 205, and aortic rings were incubated with OSI-930 (10, 100, and 1000 nM) for 24h (apoptosis-caspase 3/7 activity), 48h (cell viability), or 10d (endothelial sprout formation). For HMC-1 cells IC50 value were 14 and 34 nM in cell viability and apoptosis assay, respectively.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 18:17:38 GMT 2023` Edited by `admin` on `Fri Dec 15 18:17:38 GMT 2023`
Record UNII	G1PEG5Q9Y2
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

OSI-930

Common Name

English

OSI 930 [WHO-DD]

Common Name

English

2-THIOPHENECARBOXAMIDE, 3-((4-QUINOLINYLMETHYL)AMINO)-N-(4-(TRIFLUOROMETHOXY)PHENYL)-

Systematic Name

English

Code System Code Type Description

SMS_ID

100000178368